Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Challenges in Treating Soft Tissue Sarcomas

Case 1: 67-Year-Old Hispanic Man

Case 1: Diagnostic Workup

Case 1: Initial Treatment

Case 1: Follow-Up

Selected Therapeutic Options

Case 1: Second-Line Therapy

Trabectedin and Eribulin

PFS Benefit in Leiomyosarcoma and Liposarcoma

Other Current and Emerging Second-Line and Later Options

Concluding Remarks: Liposarcomas

Case 2: 56-Year-Old Woman With Pelvic Discomfort

Case 2: Treatment Considerations

Selected Initial Regimens for Leiomyosarcoma

Phase 1b/2 Trial of Olaratumab Plus Doxorubicin in Soft Tissue Sarcoma

GeDDiS: Randomized Phase 3 Trial of Gemcitabine Plus Docetaxel vs Doxorubicin

Case 2: Symptom Control

Concluding Remarks: Leiomyosarcoma

Abbreviations

Abbreviations (cont)